Personalizing KRAS-Mutant Allele-Specific Therapies.

Title:: Personalizing KRAS-Mutant Allele-Specific Therapies.
Document type:: Journal Article; Comment
Author(s):: Falcomatà, Chiara; Schneider, Günter; Saur, Dieter
Abstract:: KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.
Journal title abbreviation:: Cancer Discov
Year:: 2020
Journal volume:: 10
Journal issue:: 1
Pages contribution:: 23-25
Fulltext / DOI:: doi:10.1158/2159-8290.CD-19-1261
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/31919121
Print-ISSN:: 2159-8274
TUM Institution:: II. Medizinische Klinik und Poliklinik (Gastroenterologie); Lehrstuhl für Experimentelle Tumortherapie (Prof. Saur)
BibTeX

Occurrences: